Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9609 posts found.

michael_linden_300dpi

Pfizer hires new lead for gene therapy research centre

November 26, 2015 Medical Communications, Research and Development Pfizer

Pfizer has hired Professor Michael Linden to lead its new gene therapy research centre in London.  Professor Michael Linden has …
Appointment
praxbind

Boehringer’s Praxbind reversal agent wins EU approval

November 26, 2015 Medical Communications, Research and Development, Sales and Marketing

The European Commission has approved Boehringer Ingelheim’s Praxbind (idarucizumab)- a treatment to rapidly and specifically reverse the anticoagulant effects of …
News
gsk_manufactures_daraprim_for_the_uk_market

Shkreli Daraprim price U-turn prompts renewed fury

November 26, 2015 Medical Communications, Research and Development, Sales and Marketing

Turing CEO Martin Shkreli has sparked yet more criticism, after going back on a pledge to cut the price of …
News
dna

Companies face mixed fortunes in ultra-orphan approvals

November 26, 2015 Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs

UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …
Feature
gsk_boronia_australia

GSK begins Phase III study of sirukumab in giant cell arteritis

November 26, 2015 Business Services, Research and Development, Sales and Marketing GSK, Janssen

GSK today announced it has begun a Phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the …
News
10_downing_street

UK Spending Review: science budget protected, NHS gets £10 billion boost

November 25, 2015 Research and Development

Feared 40% cuts to the UK’s science budget failed to materialise today, as Chancellor George Osborne announced the budget would …
News
Takeda oncology

Challenges in oncology R&D – part 2

November 25, 2015 Manufacturing and Production, Research and Development R&D, Takeda, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
Feature
Medicines Patent Pool

BMS and Medicines Patent Pool collaborate to increase Hep C medicine access

November 25, 2015 Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C

The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
News
Teva image

Teva and Heptares enter $400m agreement for small-molecule migraine treatment

November 25, 2015 Research and Development Heptares, Teva, collaboration, migraine

Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …
News
Dementia scan

UK commits £150 million to new Dementia Research Institute

November 25, 2015 Research and Development dementia. R&D

The UK government has launched plans for a new £150 million dementia research institute that it says will drive a …
News
BMS

Bristol-Myers Squibb in new oncology collaboration

November 25, 2015 Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital

Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies.  The companies …
News
nick_plaquetec_c-4

PlaqueTec appoints Dr Nick West as CMO

November 24, 2015 Research and Development PlaqueTec

PlaqueTec has appointed Dr Nick West as its new chief medical officer.  Dr West is a research-active clinician with extensive …
Appointment
opdivo

FDA approves BMS’s Opdivo for renal cell carcinoma

November 24, 2015 Research and Development

The FDA has approved Bristol Myers Squibb’s immunotherapy Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC). …
News
Arzerra

Genmab pulls plug on Phase III Arzerra trial

November 24, 2015 Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure

Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …
News

OmniaMed UK appoints new senior management

November 24, 2015 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

OmniaMed has strengthened its senior management team by appointing Dr Clive Deverson as managing director and Dr Colin Griffin as …
Appointment
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026